DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for CPE inhibition assay are 77

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_3375	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3376	Mycophenolic Acid-Betaferon	NA	NA	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	NA	24096239
DrugRepV_3377	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3378	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3379	Avonex	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3380	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3381	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3382	Betaferon	NA	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3383	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3384	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3385	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3386	Avonex	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3387	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3388	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3389	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_3390	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_3391	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_3392	Avonex	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_3393	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_3394	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_4125	3-{3-[(1E)-1-(hydroxyimino)ethyl]phenyl}-5-methyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4126	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-methyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4127	5-ethyl-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4128	3-(3-acetylphenyl)-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4129	5-(aminomethyl)-3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4130	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-sulfanyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4131	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-(methylsulfanyl)-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4132	3-{3-[(1E)-1-(methoxyimino)ethyl]phenyl}-5-(methylamino)-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4133	5-ethyl-3-{3-[(1E)-1-{[2-(4-methylpiperazin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4134	5-ethyl-3-{3-[(1E)-1-{[2-(morpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4135	5-ethyl-3-{3-[(1E)-1-{[2-(thiomorpholin-4-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4136	3-{3-[(1E)-1-{[2-(diethylamino)ethoxy]imino}ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4137	3-{3-[(1E)-1-{[2-(cyclohexylamino)ethoxy]imino}ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4138	5-ethyl-3-{3-[(1E)-1-{[2-(piperidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4139	5-ethyl-3-{3-[(1E)-1-{[2-(pyrrolidin-1-yl)ethoxy]imino}ethyl]phenyl}-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4140	3-{3-[(1E)-1-({2-[4-(dimethylamino)piperidin-1-yl]ethoxy}imino)ethyl]phenyl}-5-ethyl-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one	NA	NA	Chikungunya virus	899	NA	CPE inhibition assay	Decrease (50 %)	NA	28619679
DrugRepV_4522	IFN-alpha2a	Antineoplastic and Immunomodulating Agents	Hepatitis C virus | Hairy cell leukemia | AIDS-related Kaposi's sarcoma | Leukemia	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved, Investigational	15200845
DrugRepV_4523	IFN-alpha2b	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4524	IFN-alphan1	Antineoplastic and Immunomodulating Agents	Venereal or genital warts caused by the Human Papiloma Virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (100 %)	Approved, Investigational	15200845
DrugRepV_4525	IFN-alphan3	NA	Condylomata acuminata	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (100 %)	Approved, Investigational	15200845
DrugRepV_4526	IFN-beta1a	Antineoplastic and Immunomodulating Agents	Multiple sclerosis | Condyloma acuminatum	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved, Investigational	15200845
DrugRepV_4527	IFN-beta1b	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (100 %)	Approved	15200845
DrugRepV_4528	Acyclovir	Dermatologicals; Antiinfectives For Systemic Use; Sensory Organ	Viral infections (Herpes simplex, Zoster and varicella zoster)	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4529	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved, Investigational	15200845
DrugRepV_4530	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (100 %)	Approved	15200845
DrugRepV_4531	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4532	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4533	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved, Investigational	15200845
DrugRepV_4534	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4535	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4536	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4537	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4538	Amantadine	Nervous System	Influenza and Parkinson Disease	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4539	Foscarnet	Antiinfectives For Systemic Use	Cytomegalovirus retinitis | Herpesviruses | Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_5069	Alisporivir	NA	Hepatitis C virus	Middle East respiratory syndrome coronavirus	N3/Jordan	NA	CPE inhibition assay	Decrease (50 %)	Investigational	27840112
DrugRepV_5070	Alisporivir	NA	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	MA-15	NA	CPE inhibition assay	Decrease (50 %)	Investigational	27840112
DrugRepV_6232	YK 51	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (92 %)	NA	20567498
DrugRepV_6233	YK 73	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (90 %)	NA	20567498
DrugRepV_6234	YK 73x	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (91 %)	NA	20567498
DrugRepV_6235	YK 101	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (94 %)	NA	20567498
DrugRepV_6236	YK 38	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (83 %)	NA	20567498
DrugRepV_7405	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7406	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7407	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7408	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7409	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7410	L-Neplanocin A	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7411	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7412	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7413	Cyclopentenyl nucleosides	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7414	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7415	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7416	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7417	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7418	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7419	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7420	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085